Oncomine Acute Myeloid Leukemia (AML) Panel – Targeted NGS Solution for AML Research
AED5,500.00The Oncomine Acute Myeloid Leukaemia (AML) Panel is a targeted next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of AML. It enables simultaneous detection of key mutations, gene fusions, and copy number variations across clinically relevant genes associated with AML.
